JanOne Inc. has just filed an international patent application for methods of using low dose naltrexone to treat chronic pain. JanOne is developing Jan123 (a novel formulation of low dose naltrexone) to treat CRPS, an orphan disease with no current FDA-approved treatments. CRPS leaves patients in debilitating pain and suffering and, as a result, often patients resort to opioid pain medications.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.01 USD | -3.14% | +2.82% | +622.52% |
05-10 | JanOne to Acquire ALT 5 Sigma | MT |
05-03 | JanOne Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+622.52% | 36.32M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- JAN Stock
- News JanOne Inc.
- Janone Inc. Files International Patent Application for Methods of Using Low Dose Naltrexone to Treat Chronic Pain